Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Preparation of agents that can successfully traverse the blood-brain-barrier (BBB) is a key challenge in brain cancer therapeutics. In this study, angiopep-2 was used as a brain-targeting peptide for preparing multifunctional Angiopep-2-modified poly nanoparticles, angiopep-2 and IP10-EGFRvIIIscFv f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuan, Xiong, Zhiyong, Liu, Zhen, Huang, Xing, Jiang, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110710/
https://www.ncbi.nlm.nih.gov/pubmed/30150691
http://dx.doi.org/10.1038/s41598-018-30072-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110710/
https://www.ncbi.nlm.nih.gov/pubmed/30150691
http://dx.doi.org/10.1038/s41598-018-30072-x

Ejemplares similares